Antiretroviral Drugs Will Retain Their Power Longer if Donors and Governments Assure Good Adherence
6/21/10
A new research study by Hoare et al in PLoS (ungated) projects that, within ten years after countries attain universal access to antiretroviral treatment for AIDS, one fifth of all patients starting treatment will never have a chance to benefit from the least-expensive and least-toxic treatments, because their initial infection will be a drug resistant strain of HIV.